Gene therapy and market access: the pharmaphorum podcastFor episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio Share XGene therapy and market access: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/gene-therapy-market-access
AMR research and Matoke Pharma: the pharmaphorum podcastRe-engineered honey has proved to be a novel and successful development for Matoke Pharma, as well as a Share XAMR research and Matoke Pharma: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/amr-research-matoke-pharma-podcast/
GSK and digital disruption: the pharmaphorum podcastDigital innovation and disruption in healthcare are the subject of this episode of the pharmaphorum podcast, for which Share XGSK and digital disruption: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/gsk-digital-disruption
Ipsen on neurotoxin research: the pharmaphorum podcastFor episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a Share XIpsen on neurotoxin research: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/ipsen-neurotoxin-research/
Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successGary Hendler, chairman and CEO of EMEA region for Eisai, talked to Richard Staines at pharmaphorum about findings Share XEisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successhttps://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/
